ROCHESTER, MI--(Marketwired - Oct 8, 2013) - OPTIMIZERx Corp. (
The Company is forecasting third quarter 2013 revenue of approximately $1.370 million, bringing revenue for the nine months of 2013 to approximately $3.142 million -- an increase of 240% over same nine month period in 2012, when revenue was $1.298 million.
The revenues were driven primarily by the Company's SampleMD solution, which generated approximately 324,756 new ePrescriptions with co-pay coupons or free sample vouchers during the third quarter, helping patients more affordably start and stay on their prescribed medications. That is a substantial increase from the 265,628 distributions in Q2 2013, and more than tripled from the 90,135 distributions in Q3 2012.
The Company's Chairman, Mr. David Harrell, stated, "We are very excited for the continued growth we're experiencing in all facets of our business, evidenced by another record quarter. We anticipate continued growth in 2014 and beyond as we expand our electronic pipeline to deliver savings and product support to hundreds of thousands of doctors -- right at point of care."
OPTIMIZERx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. For more information, please go to www.optimizerxcorp.com.
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.